Skinny
re yesterdays trading, I wonder what was the reason for the afternoon volume, either good lunches in london, or was it U.S. buying interest.I do not want a takeover in the near future as I feel all is in place for another 100 pc rise within 24 months, but, I cannot believe a large US company is not watching and knowing the short sighted Uk financial wonders they will take a nice profit if forthcoming,

re your sale note, I saw one about 10 days ago that forecast value at70p and then share magasine talked also about 70p, I wonder what they are saying this week

Now there's a bit more volume.

Standard Life < 8%

Octopus Investments > 4%

Skinny
Now u have your volume, looks like house broker has taken up the offering.
Standard dropping 500k may well be taking a profit on recent 72p purchase. They last bought at 95p,. I did read/hear somewhere that they have a limit on the amount that they will hold in any one company. Notice Octopus purchase dated last Friday so that cannot be the 72 placing as that is not yet confirmed until after the vote

nice couple of days, but must go through 95 which seems current resistance.
We might have to wait for next months results

Notice of Preliminary Results


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will announce its preliminary results for the year ended 31 December 2011 on Wednesday 7 March 2012.

A briefing for analysts will be held at 10.30am on the day of the results at the offices of Investec Bank plc, 2 Gresham Street, London EC2V 7QP.

Final Results.

Financial Highlights:

• Revenue up 8% to £34.4 million (2010: £31.9 million) at actual currency and 9% at constant currency¹

• Operating margin (pre-exceptional items²) up 190 basis points to 18.6% (2010: 16.7%)

○ Operating margin (post-exceptional items²) down 20 basis points to 13.4% (2010: 13.6%)

• Operating profit (pre-exceptional items²) up 20% to £6.4 million (2010: £5.3 million)

• Operating profit (post-exceptional items²) up 6% to £4.6 million (2010: £4.3 million)

• Basic earnings per share (pre-exceptional items²) up 11% to 4.26p (2010: 3.83p)

• Basic earnings per share (post-exceptional items²) decreased 2% to 3.10p (2010: 3.17p)

• Cash inflow from operating activities (pre-exceptional items²) of £5.5 million (2010: £8.1 million)

• Cash inflow from operating activities (post-exceptional items²) of £4.9 million (2010: £7.1 million)

• Following the acquisition of RESORBA, net debt³ was £13.4 million at 31 December 2011 (2010: net funds £3.9 million)

• Proposed final dividend of 0.305p per share, making a total dividend for the year of 0.45p per share (2010: 0.38p), an increase of 18%

Business Highlights:

• Foam revenues up 49%, driven by successful new product developments and including a customer product launch

• Foam revenues up 49%, driven by successful new product developments and including a customer product launch

• Silver alginate revenues up 5% excluding de-stocking by a major partner (down 2% including de-stocking)

• LiquiBand® revenues in Europe and the UK up 13%, maintaining our significant market positions in these geographies

• End-user sales of LiquiBand® US have increased over threefold in 2011 compared with 2010

• Successful €63.8 million acquisition in December of RESORBA, a German woundcare and wound closure business, financed by new debt and equity

• New Winsford site delivers efficiency and margin gains in its first year

TANKS - i don't know this company at all, but clearly they have pooed in their nest very badly, and on that basis alone i would not be at all tempted

Cynic
Cannot see where the drop has come from other than 1)longs at 72 wanting out with mm not giving support
2 the annual shorting , again with noq resistance from the mm
No real volume and no notice from major holders.
At recent results there were no surprises but some were expecting more.
There is a meeting of company and analysts soon

no idea ... only even looked because tanks asked me to and to comment

Annual General Meeting and Update on Trading

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting at 11.00 today.

Dr. Don Evans, Non-Executive Chairman of the Group, will make the following statement regarding current trading.

"I am pleased to report that the good start to the year, as highlighted in the 2011 Preliminary Results announcement on 7 March 2012, is continuing.

We continue to make good progress in the US market with our LiquiBand® range of products, with end-user sales increasing and further market share gains. We expect to see the impact of this progress in our ex-factory sales during the second half and we anticipate good growth for the full year. In relation to LiquiBand Flex®, we are well advanced with signing up and training distributors and are currently going through key evaluations which should be finalised by the end of the summer.

Our integration of RESORBA® is progressing to plan. We are advancing through the programme set out at the beginning of the year and we have now completed the first NHS tender for RESORBA®'s range of products, in line with our stated strategy. We expect the outcome of this first tender toward the end of the year. As a consequence of the RESORBA® acquisition, more of our Group revenues are now Euro denominated. The Group has hedged to protect profitability and, although underlying sales remain healthy, the consequent weakening of the currency could affect our headline revenue number on translation into sterling.

Elsewhere in the Group, our ActivHeal® range continues to perform well and the de-stocking effect that we experienced with one of our partners for silver alginate is now behind us. In our foam business, the targeted H2 launch of trilaminate foam dressings remains on track. However, as discussed in our Preliminary Results, 2012 foam revenues are expected to be impacted by the non-repetition of a large, roll-stock launch order in 2011, combined with our continuing strategy of focusing on higher margin business.

The effect of the expected reduction in foam revenues, together with the likely Euro impact, is that we anticipate full year Group revenues will be below expectations but with a negligible effect on profitability.

In conclusion, whilst global economic conditions remain challenging, the Board is pleased to confirm that we expect profitability for the full year 2012 to be in line with current market forecasts. The long term prospects for the Group remain excellent and we look forward to the coming months with confidence."

- ends -

First impressions look impressive with todays results, now we wait and see what the market thinks.

A buy rec in this weeks IC . shares look cheap on a discount-to-sector forward PE ratio of 14 times. Buy. Im not invested here.

Canaccord Genuity Initiates/Starts Buy TP 93p

Gone long here on AMS. Been waiting for this for a while. Now bouncing off support on gap after last results. Got plenty of broker support and outlook was pretty bullish. Worth a look.

Looks cheap forward P/E of just over
12 going into 2013.

Advanced Medical Solutions Group PLC

FORECASTS 2012 2013
Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Arden Partners
15-10-12 BUY 12.80 5.28 0.54 14.50 5.84 0.63
Peel Hunt
12-10-12 BUY 12.32 5.03 0.50 13.06 5.34 0.54
FinnCap
12-10-12 HOLD 12.10 5.70 0.50 14.00 6.90 0.50
Shore Capital
05-10-12 HOLD 12.10 5.10 0.60 14.80 5.90 0.70
Investec Securities
05-10-12 BUY 12.80 5.20 0.50 14.80 6.00 0.60
N+1 Brewin
04-10-12 HOLD 11.90 4.80 0.50 13.10 5.20 0.60
N+1 Singer
25-09-12 BUY 12.30 5.10 0.60 14.40 5.90 0.60
Canaccord Genuity Ltd
20-09-12 BUY 12.43 5.01 0.50 14.12 5.23 0.50
Nomura Code
13-09-12 BUY 12.80 5.32 0.51 14.40 5.69 0.57
Seymour Pierce
02-07-12 BUY 12.30 5.10 14.20 5.50
Numis Securities Ltd
22-06-12 BUY 12.90 5.45 0.54 15.20 6.42 0.65

2012 2013
Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)
Consensus 12.43 5.19 0.52 14.13 5.81 0.58
1 Month Change -0.00 0.08 -0.01 -0.10 0.07 -0.02
3 Month Change -0.02 0.08 -0.00 -0.07 0.08 -0.03


GROWTH
2011 (A) 2012 (E) 2013 (E)
Norm. EPS 10.79% 24.48% 11.92%
DPS % -0.19% 10.30%

INVESTMENT RATIOS
2011 (A) 2012 (E) 2013 (E)

EBITDA £7.78m £15.54m £17.21m
EBIT £6.40m £12.45m £14.44m
Dividend Yield 0.73% 0.73% 0.80%
Dividend Cover 7.95x 9.91x 10.06x
PER 17.26x 13.86x 12.39x
PEG 1.60f 0.57f 1.04f
Net Asset Value PS 5.97p 36.15p 41.26p

As per above.....

Trading Update

Hmm, sp taken a hefty knock, not sure that it is entirely justified but there are no prisoners taken in this sector.

positive rns yesterday, see what trading update end june brings